BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Avant Immunotherapeutics 

Name change to Celldex Therapeutics
Press releases archived for reference only.
Needham  Massachusetts    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS

View Clinical Trials from BioPharm Insight









 Company News
Avant Immunotherapeutics Announces Name Change to Celldex Therapeutics, Inc.; Anthony S. Marucci Appointed President and CEO 9/29/2008 8:48:04 AM    More...
Avant Immunotherapeutics (AVAN) CEO To Present at the UBS Warburg 2008 Global Life Sciences Conference September 23 9/19/2008 9:42:49 AM    More...
Avant Immunotherapeutics (AVAN) CEO to Present at the 28th Annual Canaccord Adams Global Growth Conference 8/9/2008 11:25:40 PM    More...
Avant Immunotherapeutics (AVAN) to Report Second Quarter 2008 Financial Results on August 6, 2008 8/4/2008 12:53:35 PM    More...
3M Drug Delivery Systems Collaborates with Avant Immunotherapeutics (AVAN) on Vaccine Adjuvants 6/11/2008 9:00:42 AM    More...
Avant Immunotherapeutics (AVAN) CEO to Present at the Needham & Company Biotechnology & Medical Technology Conference 6/4/2008 10:01:23 AM    More...
National Institutes of Health (NIH) Initiates Phase 1 Safety Study of Avant Immunotherapeutics (AVAN)'s Oral Combined Enterotoxigenic E. coli-Cholera Vaccine 6/4/2008 8:44:28 AM    More...
Avant Immunotherapeutics (AVAN) Data Shows Brain Cancer Vaccine Doubles Survival 6/3/2008 6:15:36 AM    More...
Avant Immunotherapeutics (AVAN) Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 5/22/2008 1:29:49 PM    More...
Avant Immunotherapeutics (AVAN) Announces Hart-Scott Rodino Clearance to License Cancer Vaccine to Pfizer Inc. (PFE) 5/21/2008 7:45:57 AM    More...
12345678910...